Elanco Animal Health Incorporated Common Stock
ELANElanco Animal Health Incorporated is a global company focused on developing, manufacturing, and marketing products for animal health. It specializes in veterinary pharmaceuticals, vaccines, and nutritional products aimed at enhancing the health and well-being of pets and livestock. Founded in 1954 and headquartered in Greenfield, Indiana, Elanco serves a broad customer base across multiple markets, emphasizing innovation in animal healthcare.
Company News
KeyBanc Capital Markets initiated coverage on Elanco Animal Health, rating it Overweight with a $27 price target. The analyst believes the company's innovative pet care products and improving financial metrics make the stock undervalued.
The global companion animal health market is projected to grow from USD 25.28 billion in 2024 to USD 61.74 billion by 2034, driven by rising pet ownership, pet humanization trends, and advances in veterinary technologies.
Elanco Animal Health reported Q2 2025 earnings with revenue of $1,241 million, beating estimates. The company saw strong performance in pet and farm animal health segments, driven by innovative product launches, though profitability metrics weakened due to higher operating expenses.
Elanco Animal Health has divested its aqua business to Merck Animal Health for $1.3 billion, enabling the company to focus on pet health and livestock sustainability while reducing its debt burden.
The deal “allows us to prioritize our investments in larger markets with greater earnings potential over the medium and long term, while creating balance sheet flexibility,” Elanco Animal Health said in a statement.
